




Instance: composition-en-28443e1a5133f6583423ca208758fe45
InstanceOf: CompositionUvEpi
Title: "Composition for gliolan Package Leaflet"
Description:  "Composition for gliolan Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfae6a04761fe4504faaf2d44cb5ce1db)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - gliolan"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Gliolan is and what it is used for </li>
<li>What you need to know before you take Gliolan </li>
<li>How to take Gliolan </li>
<li>Possible side effects </li>
<li>How to store Gliolan </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What gliolan is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What gliolan is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Gliolan is used for the visualisation of certain brain tumours (called malignant glioma) during tumour 
surgery. </p>
<p>Gliolan contains a substance called aminolevulinic acid (5-ALA). 5-ALA accumulates preferably in 
tumour cells where it is transformed into another similar substance. If the tumour is then exposed to 
blue light, this new substance emits a red-violet light which helps to better see what is normal tissue 
and what is tumour tissue. This helps the surgeon to remove the tumour while sparing healthy tissue. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take gliolan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take gliolan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Gliolan 
* if you are allergic to 5-ALA or porphyrins. 
* in case of known or suspected acute or chronic types of porphyria (i.e. inherited or acquired 
disorders of certain enzymes in the synthesis pathway of red blood pigment). 
* in case of known or suspected pregnancy. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Gliolan. 
* For 24 hours after administration of this medicine, protect your eyes and skin from strong 
light (for example direct sunlight or brightly focused indoor light). 
* If you have a heart disease or had heart disease in the past, you should tell your doctor. In this 
case, this medicine should be used with caution because your blood pressure may be decreased. </p>
<p>Renal or hepatic impairment 
No trials have been performed in patients with poor liver or kidney function. Therefore, this medicine 
should be used with caution in such patients.  </p>
<p>Elderly 
There are no special instructions for use in elderly patients with normal organ function. </p>
<p>Children and adolescents (&lt; 18 years) 
There is no experience with Gliolan in children and adolescents. Therefore this medicine is not 
recommended in this age group. </p>
<p>Other medicines and Gliolan 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines, particularly medicines that may cause skin problems when the skin comes under strong 
light (for example some types of medicines called antibiotics), but also medicines obtained without 
prescription (for example hypericin or Saint John s wort extracts). </p>
<p>One case of severe sunburn lasting for 5 days has been reported in a patient after having taken this 
medicine and a hypericin extract. You should not take any such products up to 2 weeks after you have 
taken Gliolan. </p>
<p>Within 24 hours after having taken Gliolan, avoid any other medicines that may harm the liver. </p>
<p>Gliolan with food and drink 
This medicine is generally used once only, namely 2-4 hours before anaesthesia for surgery for certain 
brain tumours called glioma. You should not drink or eat for at least 6 hours before anaesthesia. </p>
<p>Pregnancy and breast-feeding 
Pregnancy 
It is not known whether Gliolan will harm an unborn baby. Do not use this medicine if you are 
pregnant.  </p>
<p>Breast-feeding 
It is not known whether this medicine enters breast milk. Breast-feeding mothers should not 
breast-feed for 24 hours after treatment with this medicine. </p>
<p>Driving and using machines 
This medicine itself has no influence on the ability to drive and use machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take gliolan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take gliolan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>This medicine is a powder that must be first mixed with drinking water before use. This is always 
done by a pharmacist or a nurse and not by yourself. The usual dose is 20 mg 5-ALA HCl per 
kilogram body weight. The pharmacist or nurse will calculate the exact dose you need and the amount 
of the solution (in ml) you have to drink. You have to drink the prepared solution 2-4 hours before 
anaesthesia. </p>
<p>If the surgery is postponed by more than 12 hours, surgery should be re-scheduled for the next day or 
later. Another dose of this medicine can be taken 2   4 hours before anaesthesia. </p>
<p>If you take more Gliolan than you should 
If you have taken more Gliolan than you should, your doctor will decide on any necessary measures to 
avoid any problems, including sufficient protection from strong light (for example direct sunlight). </p>
<p>If you forget to take Gliolan 
This medicine is given once only at the day of surgery, 2   4 hours before start of anaesthesia. If you 
have forgotten to take this medicine during this time period, it is not advisable to take it just before 
start of anaesthesia. In this case, anaesthesia and surgery must be postponed for at least 2 hours, if 
possible. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Most serious side effects include mild alterations of blood cell counts (red and white cells, platelets), 
disorders that affect the nervous system (neurological disorders) like partial paralysis of one side of 
the body (hemiparesis) and blood clots that may obstruct blood vessels (thromboembolism). Further 
frequently observed side effects are being sick (vomiting), feeling sick (nausea) and slight increase of 
some enzymes (transaminases,  -GT, amylase) or bilirubin (a bile pigment produced in the liver by 
breakdown of red blood pigment) in the blood.  </p>
<p>Tell your doctor immediately if you experience any complaints. </p>
<p>Side effects are divided into the following two categories: 
* immediate side effects after having taken Gliolan and before anaesthesia 
* combined side effects of Gliolan, anaesthesia, and tumour resection. </p>
<p>After having taken Gliolan and before start of anaesthesia, the following side effects may occur:  </p>
<p>Uncommon side effects (may affect up to 1 in 100 people): 
Feeling sick (nausea), decrease of blood pressure (hypotension), skin reactions (for example rash, 
looking like sunburn). </p>
<p>In combination with anaesthesia and tumour resection further side effects may occur:<br />
Very common side effects (may affect more than 1 in 10 people): 
Mild alterations of blood cell counts (red and white cells, platelets), and slight increase of some 
enzymes (transaminases,  -GT, amylase) or bilirubin (a bile pigment produced in the liver by 
breakdown of red blood pigment) in the blood. These changes peak between 7 and 14 days after 
surgery. The changes will completely resolve within a few weeks. Usually you will not 
experience any symptoms when these changes occur. </p>
<p>Common side effects (may affect up to 1 in 10 people): 
Feeling sick (nausea), being sick (vomiting), disorders that affect the nervous system 
(neurological disorders) like partial paralysis of one side of the body (hemiparesis), total or partial 
loss of ability to use or understand language (aphasia), seizures (convulsions) and blindness for 
half the field of vision in one or both eyes (hemianopsia), and blood clots that may obstruct blood 
vessels (thromboembolism). </p>
<p>Uncommon side effects (may affect up to 1 in 100 people): 
Decrease of blood pressure (hypotension), brain swelling (brain oedema). </p>
<p>Very rare side effects (may affect up to 1 in 10 000 people) or not known (frequency cannot 
be estimated from the available data): 
Decrease of your sense of touch (hypaesthesia), and loose or watery stools (diarrhoea).  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store gliolan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store gliolan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date 
refers to the last day of that month. </p>
<p>Keep the bottle in the outer carton in order to protect from light. </p>
<p>The reconstituted solution is physically-chemically stable for 24 hours at 25  C. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Gliolan contains 
The active substance is 5-aminolevulinic acid hydrochloride (5-ALA HCl). One bottle contains 1.17 g 
of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-ALA HCl. 
One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl. </p>
<p>What Gliolan looks like and contents of the pack 
This medicine is a powder for oral solution. The powder is a white to off-white cake. The reconstituted 
solution is a clear and colourless to slightly yellowish fluid.<br />
Gliolan is provided in a glass bottle and presented in packs of 1, 2 and 10 bottles. Not all pack sizes 
may be marketed.  </p>
<p>Marketing Authorisation Holder 
photonamic GmbH &amp; Co. KG 
Eggerstedter Weg 25421 Pinneberg 
Germany </p>
<p>Manufacturer 
Lyocontract GmbH 
Pulverwiese 1 
38871 Ilsenburg 
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien, Nederland 
Pharmanovia Benelux B.V. 
Burgemeester Gulj laan 2<br />
NL-4837 CZ Breda 
Nederland/Pays-Bas/Niederlande 
Tel/T l: + 31 (0)76 5600info.benelux@pharmanovia.com </p>
<p>Italia 
medac pharma s.r.l. a socio unico 
Via Viggiano I-00178 Roma 
Tel: + 39 06 51 59 info@medacpharma.it </p>
<p>, Deutschland, Eesti,  , 
Hrvatska,  sland,  , Latvija, Lietuva, 
Luxembourg/Luxemburg, Magyarorsz g, 
Malta,  sterreich, Rom nia, Slovenija/ 
United Kingdom (Northern Ireland) 
medac GmbH 
Theaterstra e 6<br />
D-22880 Wedel 
 /Deutschland/Saksamaa/ / 
Njema ka/ skaland/V cija/Vokietija/ 
Allemagne/N metorsz g/Il- ermanja/Germania/ 
Nem ija/Germany 
Te ./Tel/S mi/ /T l: + 49 (0)4103 8006-0 
gliolan@medac.de </p>
<p>Norge 
medac Gesellschaft f r klinische 
Spezialpr parate G.m.b.H, Tyskland, filial 
Postboks N-1312 Slependen 
Tlf: +47 90 63 81 Polska 
medac GmbH Sp. z o.o. 
Oddzia  w Polsce 
ul Post pu 21 B 
PL-02-676 Warszawa 
Tel.: + 48 22 430 00 kontakt@medac.pl </p>
<p>esk  republika 
medac GmbH organiza n  slo ka 
Horn  CZ 639 00 Brno 
Tel: + 420 543 233 info@medac.eu </p>
<p>Portugal 
medac GmbH 
sucursal em Portugal 
Alameda Ant nio S rgio n 22 6 C 
P-1495-132 Alg s 
Tel: + 351 21 410 75 83/4 
geral@medac.de </p>
<p>Danmark 
medac Gesellschaft f r klinische 
Spezialpr parate G.m.b.H, Tyskland, filial 
Bagerstr de 28, 1. DK-4640 Faxe 
Tlf: +46 (0)44 7850 Slovensk  republika 
medac GmbH 
organiza n  zlo ka Slovensko 
Staromestsk  3 
SK-811 03 Bratislava 
Tel: + 420 543 233 info@medac.eu </p>
<p>Espa a 
Laboratorios Gebro Pharma, S.A. 
Tel: + 34 93 205 86 Suomi/Finland 
medac Gesellschaft f r klinische 
Spezialpr parate G.m.b.H, Tyskland, filial 
Spektri Business Park 
Mets nneidonkuja 4 
FIN-02130 Espoo 
Puh/Tel: + 358 (0)10 420 4France 
medac SAS 
1 rue Croix Barret 
F-69007 Lyon 
T l: + 33 (0)4 37 66 14 infomed@medac.fr </p>
<p>Sverige 
medac Gesellschaft f r klinische 
Spezialpr parate G.m.b.H, Tyskland, filial 
Hyllie Boulevard S-215 32 Malm<br />
Tel: +46 (0)44 7850 Ireland 
Fannin Ltd 
Fannin House 
South County Business Park 
Leopardstown 
IRL - Dublin Tel: + 353 (0)1 290 7medical@dccvital.com </p>
<p>This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-28443e1a5133f6583423ca208758fe45
InstanceOf: CompositionUvEpi
Title: "Composition for gliolan Package Leaflet"
Description:  "Composition for gliolan Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfae6a04761fe4504faaf2d44cb5ce1db)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - gliolan"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Gliolan 
3. Sådan skal du tage Gliolan 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What gliolan is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What gliolan is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Gliolan bruges til visualisering af visse hjernesvulster (som kaldes for malignt gliom) under kirurgisk 
fjernelse af svulsten.  </p>
<p>Gliolan indeholder et stof, der hedder aminolevulinsyre (5-ALA). 5-ALA akkumuleres især i 
svulstceller, hvor det omdannes til et andet lignende stof. Hvis svulsten derefter eksponeres for blåt 
lys, udstråler dette nye stof et rød-violet lys, som gør det nemmere at se, hvad der er normalt væv, og 
hvad der er svulstvæv. Dette hjælper kirurgen til at fjerne svulsten, samtidig med at det raske væv 
skånes. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take gliolan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take gliolan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Gliolan </p>
<ul>
<li>
<p>hvis du er allergisk over for 5-ALA eller porfyriner. </p>
</li>
<li>
<p>i tilfælde af kendte eller mistænkte akutte eller kroniske former for porfyri (dvs. nedarvede eller 
erhvervede defekter i visse enzymer i syntesen af rødt blodpigment). </p>
</li>
<li>
<p>hvis du er gravid eller har formodning om, at du er gravid. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Gliolan. </p>
<ul>
<li>
<p>I 24 timer efter indgivelse af dette lægemiddel skal du beskytte dine øjne og huden mod for 
kraftigt lys (for eksempel direkte sollys eller indendørsbelysning med kraftig fokus). </p>
</li>
<li>
<p>Hvis du har en hjertesygdom eller tidligere har haft en hjertesygdom, bør du fortælle det til din 
læge. I så fald skal dette lægemiddel bruges med forsigtighed, da blodtrykket kan blive nedsat. </p>
</li>
</ul>
<p>Nedsat nyre- eller leverfunktion 
Der er ikke lavet undersøgelser på patienter med nedsat lever- eller nyrefunktion. Dette lægemiddel 
skal derfor anvendes med forsigtighed til sådanne patienter.  </p>
<p>Ældre 
Der er ingen særlige instruktioner for anvendelse til ældre patienter med normal organfunktion. </p>
<p>Børn og unge (&lt; 18 år) 
Der er ingen erfaring med anvendelse af dette lægemiddel til børn og unge. Dette lægemiddel frarådes 
derfor til denne aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med Gliolan 
Fortæl altid lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget andre 
lægemidler eller planlægger at tage andre lægemidler. Dette gælder især lægemidler, som kan give 
hudproblemer, når huden udsættes for kraftigt lys (for eksempel nogle typer lægemidler, der kaldes for 
antibiotika), men det gælder også lægemidler, som ikke er købt på recept (for eksempel 
hypericinekstrakter eller perikon). </p>
<p>For en enkelt patient er der indberettet et enkelt tilfælde af svær solforbrænding, der varede i 5 dage, 
efter at dette lægemiddel og et hypericin (perikon) ekstrakt blev taget samtidigt. Du bør ikke indtage 
sådanne stoffer, før der er gået 2 uger efter, at du har taget Gliolan. </p>
<p>Andre lægemidler, som kan beskadige leveren, skal undgås inden for 24 timer efter anvendelse af 
Gliolan. </p>
<p>Brug af Gliolan sammen med mad og drikke 
Dette lægemiddel bruges normalt kun én gang, nemlig 2-4 timer inden bedøvelsen i forbindelse med 
en operation, hvor en type hjernesvulst, der kaldes for gliom, skal fjernes. Du må ikke indtage mad og 
drikkevarer i mindst 6 timer inden bedøvelsen. </p>
<p>Graviditet og amning 
Graviditet 
Det er ukendt, om Gliolan kan skade et ufødt barn. Brug ikke dette lægemiddel, hvis du er gravid.  </p>
<p>Amning 
Det er ukendt, om dette lægemiddel kan trænge over i modermælken. Ammende mødre skal afbryde 
amningen i 24 timer efter behandling med dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Dette lægemiddel medfører i sig selv ingen påvirkning af evnen til at føre motorkøretøj og betjene 
maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take gliolan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take gliolan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel er et pulver, som først skal blandes med drikkevand inden brug. Dette gøres altid af 
apotekspersonalet eller en sygeplejerske - ikke af dig selv. Den normale dosis er 20 mg 5-ALA HCl 
pr. kilogram legemsvægt. Apotekeren eller sygeplejersken vil beregne den nøjagtige dosis, som du har 
brug for, og den mængde opløsning (i ml), som du skal drikke. Du skal drikke den tilberedte opløsning 
2-4 timer inden bedøvelsen. </p>
<p>Hvis operationen udsættes mere end 12 timer, bør operationen udskydes til næste dag eller senere. Der 
kan tages en ekstra dosis af dette lægemiddel 2-4 timer inden anæstesi (bedøvelse). </p>
<p>Hvis du har taget for meget Gliolan 
Hvis du har taget for meget Gliolan, vil din læge træffe foranstaltninger for at undgå eventuelle 
problemer, herunder sørge for tilstrækkelig beskyttelse mod stærkt lys (for eksempel direkte sollys). </p>
<p>Hvis du har glemt at tage Gliolan 
Dette lægemiddel gives kun én gang på dagen for operationen 2-4 timer inden bedøvelsen. Hvis du har 
glemt at tage lægemidlet i denne periode, bør du ikke tage lægemidlet umiddelbart inden bedøvelsen. I 
det tilfælde skal bedøvelsen og operationen om muligt udsættes i mindst 2 timer. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>De alvorligste bivirkninger omfatter milde forstyrrelser af blodlegemetallene (røde og hvide 
blodlegemer, blodplader), forstyrrelser, der kan påvirke nervesystemet (neurologiske forstyrrelser) 
såsom delvis paralysering af den ene side af kroppen (hemiparese) og blodpropper, der kan sætte sig 
fast i blodkarrene (tromboemboli). Derudover er flg. bivirkninger set hyppigt: opkastning, kvalme og 
let forhøjede enzymer (transaminase, gammaglutamyltransferase, amylase) eller bilirubin (et 
galdefarvestof, der produceres i leveren ved nedbrydning af rødt blodpigment) i blodet. </p>
<p>Fortæl det straks til lægen, hvis du får det dårligt. </p>
<p>Bivirkningerne er opdelt i to kategorier: </p>
<ul>
<li>
<p>Øjeblikkelige bivirkninger efter indtagelse af Gliolan og før anæstesi </p>
</li>
<li>
<p>Kombinerede bivirkninger af Gliolan, anæstesi og fjernelse af svulsten. </p>
</li>
</ul>
<p>Nedenstående bivirkninger kan opstå, efter at du har taget Gliolan og inden bedøvelsen:<br />
Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 behandlede): 
kvalme, nedsat blodtryk (hypotension), hudreaktioner (for eksempel udslæt, som ligner en 
solforbrænding). </p>
<p>Andre bivirkninger kan opstå efter kombination med bedøvelse og fjernelse af svulsten:<br />
Meget almindelige bivirkninger (kan forekomme hos 1 ud af 10 behandlede): 
mindre ændringer i blodværdier (røde og hvide blodlegemer, blodplader), svag stigning i nogle 
enzymer (transaminaser, γ-GT, amylase) eller bilirubin (et galdefarvestof, som produceres i 
leveren ved nedbrydning af rødt blodpigment) i blodet. Disse ændringer når deres maksimum 
mellem 7 og 14 dage efter det kirurgiske indgreb. Ændringerne er fuldstændigt forsvundet inden 
for få uger. Normalt vil du ikke få nogen symptomer, når disse ændringer opstår. </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 behandlede): 
kvalme, opkastning, forstyrrelser, der kan påvirke nervesystemet (neurologiske forstyrrelser) 
såsom delvis paralysering af den ene side af kroppen (hemiparese), hel eller delvis tab af evnen til 
at bruge eller forstå sprog (afasi), kramper og tab af synet i halvdelen af synsfeltet i det ene eller 
begge øjne (hemianopsi) og blodpropper, som kan blokere blodkarrene (tromboemboli). </p>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 behandlede): 
nedsat blodtryk (hypotension), hævelse i hjernen (hjerneødem).  </p>
<p>Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10 000 behandlede) eller ikke 
kendt hyppighed (kan ikke estimeres ud fra forhåndenværende data): 
nedsat følesans (hypæstesi) og løs eller vandig afføring (diaré). </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store gliolan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store gliolan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken efter EXP. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Opbevar flasken i den ydre karton for at beskytte mod lys.  </p>
<p>Den rekonstituerede opløsning er fysisk-kemisk stabil i 24 timer ved 25 ºC. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Gliolan indeholder: 
Aktivt stof: 5-aminolevulinsyrehydrochlorid (5-ALA HCl). En flaske indeholder 1,17 g 
5-aminolevulinsyre (5-ALA) svarende til 1,5 g 5-ALA HCl. 
En ml fortyndet opløsning indeholder 23,4 mg 5-ALA svarende til 30 mg 5-ALA HCl. </p>
<p>Udseende og pakningsstørrelser 
Dette lægemiddel er et pulver til opløsning, der skal drikkes. Pulveret er en hvid til råhvid klump. Den 
rekonstituerede opløsning er en klar og farveløs til lysegul væske.<br />
Gliolan fås i pakninger med 1, 2 og 10 flasker. Ikke alle pakningsstørrelser er nødvendigvis 
markedsført.  </p>
<p>Indehaver af markedsføringstilladelsen 
photonamic GmbH &amp; Co. KG 
Eggerstedter Weg 25421 Pinneberg 
Tyskland </p>
<p>Fremstiller 
Lyocontract GmbH<br />
Pulverwiese 1 
38871 Ilsenburg 
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien, Nederland 
Pharmanovia Benelux B.V. 
Burgemeester Guljélaan 2<br />
NL-4837 CZ Breda 
Nederland/Pays-Bas/Niederlande 
Tel/Tél: + 31 (0)76 5600info.benelux@pharmanovia.com </p>
<p>Italia 
medac pharma s.r.l. a socio unico 
Via Viggiano I-00178 Roma 
Tel: + 39 06 51 59 info@medacpharma.it </p>
<p>България, Deutschland, Eesti, Ελλάδα, 
Hrvatska, Ísland, Κύπρος, Latvija, Lietuva, 
Luxembourg/Luxemburg, Magyarország, 
Malta, Österreich, România, Slovenija/ 
United Kingdom (Northern Ireland) 
medac GmbH 
Theaterstraße 6<br />
D-22880 Wedel 
Германия/Deutschland/Saksamaa/Γερμανία/ 
Njemačka/Þýskaland/Vācija/Vokietija/ 
Allemagne/Németország/Il-Ġermanja/Germania/ 
Nemčija/Germany 
Teл./Tel/Sími/Τηλ/Tél: + 49 (0)4103 8006-0 
gliolan@medac.de </p>
<p>Norge 
medac Gesellschaft für klinische 
Spezialpräparate G.m.b.H, Tyskland, filial 
Postboks N-1312 Slependen 
Tlf: +47 90 63 81<br />
Polska 
medac GmbH Sp. Z o.o. 
Oddział w Polsce 
ul Postępu 21 B 
PL-02-676 Warszawa 
Tel.: + 48 22 430 00 kontakt@medac.pl </p>
<p>Česká republika 
medac GmbH organizační složka 
Horní CZ 639 00 Brno 
Tel: + 420 543 233 info@medac.eu </p>
<p>Portugal 
medac GmbH 
sucursal em Portugal 
Alameda António Sérgio nº22 6ºC 
P-1495-132 Algés 
Tel: + 351 21 410 75 83/4 
geral@medac.de </p>
<p>Danmark 
medac Gesellschaft für klinische 
Spezialpräparate G.m.b.H, Tyskland, filial 
Bagerstræde 28, 1. DK-4640 Faxe 
Tlf: +46 (0)44 7850<br />
Slovenská republika 
medac GmbH 
organizačná zložka Slovensko 
Staromestská 3 
SK-811 03 Bratislava 
Tel: + 420 543 233 info@medac.eu </p>
<p>España 
Laboratorios Gebro Pharma, S.A. 
Tel: + 34 93 205 86 Suomi/Finland 
medac Gesellschaft für klinische 
Spezialpräparate G.m.b.H, Tyskland, filial 
Spektri Business Park 
Metsänneidonkuja 4 
FIN-02130 Espoo 
Puh/Tel: + 358 (0)10 420 4 
France 
medac SAS 
1 rue Croix Barret 
F-69007 Lyon 
Tél: + 33 (0)4 37 66 14 infomed@medac.fr </p>
<p>Sverige 
medac Gesellschaft für klinische 
Spezialpräparate G.m.b.H, Tyskland, filial 
Hyllie Boulevard S-215 32 Malmö 
Tel: +46 (0)44 7850  </p>
<p>Ireland 
Fannin Ltd 
Fannin House 
South County Business Park 
Leopardstown 
IRL - Dublin Tel: + 353 (0)1 290 7medical@dccvital.com </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-28443e1a5133f6583423ca208758fe45
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for gliolan Package Leaflet for language en"
Description: "ePI document Bundle for gliolan Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-28443e1a5133f6583423ca208758fe45"
* entry[0].resource = composition-en-28443e1a5133f6583423ca208758fe45

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp28443e1a5133f6583423ca208758fe45"
* entry[=].resource = mp28443e1a5133f6583423ca208758fe45
                            
                    
Instance: bundlepackageleaflet-da-28443e1a5133f6583423ca208758fe45
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for gliolan Package Leaflet for language da"
Description: "ePI document Bundle for gliolan Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-28443e1a5133f6583423ca208758fe45"
* entry[0].resource = composition-da-28443e1a5133f6583423ca208758fe45

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp28443e1a5133f6583423ca208758fe45"
* entry[=].resource = mp28443e1a5133f6583423ca208758fe45
                            
                    



Instance: mp28443e1a5133f6583423ca208758fe45
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Gliolan 30 mg/ml powder for oral solution."
Description: "Gliolan 30 mg/ml powder for oral solution."
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/07/413/001-003"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Gliolan 30 mg/ml powder for oral solution."
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 28443e1a5133f6583423ca208758fe45ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "gliolan"

* status = #current
* mode = #working

* title = "List of all ePIs associated with gliolan"

* subject = Reference(mpfae6a04761fe4504faaf2d44cb5ce1db)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#gliolan "gliolan"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-28443e1a5133f6583423ca208758fe45) // gliolan en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-28443e1a5133f6583423ca208758fe45) // gliolan da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-28443e1a5133f6583423ca208758fe45
InstanceOf: List

* insert 28443e1a5133f6583423ca208758fe45ListRuleset
    